On January 20, 2026, Cencora, Inc. announced the election of Ellen Cooper—Chairman, President and CEO of Lincoln Financial—as an independent director, marking a strategic enhancement of its governance. Cooper brings more than 25 years of experience in risk management and financial services, having previously served as Executive Vice President and Chief Investment Officer at Lincoln Financial and as Global Head of Insurance Strategy at Goldman Sachs Asset Management. Her credentials include a BBA from Temple University, Fellowship of the Society of Actuaries, and CFA charter. This addition expands Cencora’s board expertise in complex, regulated industries, supporting its aim to sustain long-term growth and oversee the company’s operations, which encompass a 51,000-member global workforce and more than $300 billion in annual revenue.

Cencora has entered into a strategic collaboration with Curant Rare to deliver integrated commercialization solutions for rare and orphan drug therapies, leveraging Cencora’s pharmaceutical logistics, pharmacovigilance and market-access platforms alongside Curant Rare’s specialty pharmacy and omnichannel patient engagement services. The initiative targets the unique challenges of rare disease drug launches—complex regulatory approvals, limited patient populations and high cost of goods—by streamlining supply chain operations and accelerating therapy availability. Investors should note that this alliance positions Cencora to capture a larger share of the fast-growing rare disease segment, estimated to represent over 10% of global pharmaceutical revenues by 2030, while enhancing margins through value-added service offerings.